Novo Nordisk

Adimab Provides 2021 Update on Clinical Pipeline

Retrieved on: 
Wednesday, January 19, 2022
Health, Clinical Trials, Regeneron Pharmaceuticals, Acceleron, Human, Nextpoint, Monoclonal antibody, Biotechnology, Antibody, BLA, Lilly, Sanofi, Philosophy, Sintilimab, Novartis, Partner, Merck, Boehringer Ingelheim, Biogen, GSK, Therapy, Mapp Biopharmaceutical, Mouse, CD3, Bristol Myers Squibb, FDA, Engineering, LLC, Top of the Form (quiz show), Novo Nordisk, Fine chemical, Pharmaceutical industry, Cidariini, Cultural icon, Takeda, Biotechnology Innovation Organization, Fourth, fifth, and sixth derivatives of position

In 2021, Innovent and Lilly filed a BLA with the FDA for approval in the United States.

Key Points: 
  • In 2021, Innovent and Lilly filed a BLA with the FDA for approval in the United States.
  • In 2021, Adimab partners exercised 10 commercial licenses to advance programs into development, bringing the total number of optioned programs to more than 85.
  • Adimab focuses solely on its partners and not on developing an internal product pipeline.
  • Since 2009, Adimab has partnered with 95 pharmaceutical and biotechnology companies, generating 425 therapeutic programs, 55 clinical programs, and its first approved product.

Health2Sync Expands Product Offering in Chronic Disease Management with Real Word Data Integration and Analytics

Retrieved on: 
Tuesday, January 18, 2022
Ministry, Patient, Health status of Asian Americans, Ministry of Health (Saudi Arabia), Insulin, Exercise, Healthline, Sanofi, Partnership, Support, CEO, Degenerative disease, Disease, Solution, Severe cognitive impairment, Diet, Astellas Pharma, Diabetes, Single-frequency network, Disease management, View, Industry, Blood pressure, Ecosystem, Triage, Chronic kidney disease, Goal, Fitbit, FreeStyle, Blood, Efficiency, Glycated hemoglobin, Conditional sentence, Multimedia, Risk, Communication, CGM, Decision-making, Software, Amputation, Dialysis, Hospital, Novo Nordisk, Physician, Policy, Medical device, Pharmaceutical industry, Health insurance, Mallya, Health

The Health2Sync app allows individuals to visualize personal information regarding CGM statistics, blood pressure, diet, exercise, and weight.

Key Points: 
  • The Health2Sync app allows individuals to visualize personal information regarding CGM statistics, blood pressure, diet, exercise, and weight.
  • The cloud-based data analytics program also enables improved patient management efficiency and decision making, comorbidity tracking, triage, and bi-directional communication.
  • "Health2Sync solves the disconnect in traditional chronic disease management," said Ed Deng, Co-founder and CEO of Health2Sync.
  • Established in 2013, Health2Sync aims to provide personalized and scalable digital solutions for chronic disease patients.

Adimab Provides Year-End Update on 2021 Partnership Activities

Retrieved on: 
Wednesday, January 12, 2022
Medical Devices, Health, Research, Pharmaceutical, Science, Biotechnology, Regeneron Pharmaceuticals, Acceleron, Human, Nextpoint, Monoclonal antibody, Rest, Biotechnology, Antibody, Lilly, Sanofi, Achievement, Novartis, Merck, Solution, Boehringer Ingelheim, Biogen, GSK, Industry, VVB, Therapy, Â, Mouse, CD3, Bristol Myers Squibb, Engineering, LLC, Top of the Form (quiz show), Novo Nordisk, Pharmaceutical industry, Takeda, Biotechnology Innovation Organization, Fourth, fifth, and sixth derivatives of position

In addition, Adimab announced the expansion of 14 of its current partnerships and the achievement of 52 technical and development milestones across numerous collaborations.

Key Points: 
  • In addition, Adimab announced the expansion of 14 of its current partnerships and the achievement of 52 technical and development milestones across numerous collaborations.
  • New alliances for 2021 include collaborations with 3T Biosciences, 76 Bio, Inc., Adaptate Biotherapeutics, Celsius Therapeutics, Ikaika Therapeutics, Inc., Stellanova, and VVB, among others.
  • In addition, Adimab expanded its collaborations with Adagio Therapeutics, Alector, Amagma, Innovent, iTeos, Link Immunotherapeutics, Mersana Therapeutics, Inc., NextPoint, Regeneron, Sensei Biotherapeutics, and Takeda, among others.
  • In 2021, Adimab and its partners initiated over 60 new therapeutic programs, bringing the total number of royalty-bearing programs to 425.

Novo Seeds Provides Business Update on a Record Year - Building Exceptional Companies for Global Impact

Retrieved on: 
Wednesday, January 12, 2022
Novo Nordisk Foundation, IPO, Growth, NASDAQ, Organon, Novo Nordisk, Industry, Therapy, Seed, Novo Holdings A/S, VCS, Investment, Fine chemical, Financial services, Nordic

Novo Seeds' commitment to early-stage financing and venture creation resulted in an unprecedented amount of capital and interest from fellow VCs across Europe and the US in 2021, with over US$ 550 million raised by Novo Seeds' portfolio companies.

Key Points: 
  • Novo Seeds' commitment to early-stage financing and venture creation resulted in an unprecedented amount of capital and interest from fellow VCs across Europe and the US in 2021, with over US$ 550 million raised by Novo Seeds' portfolio companies.
  • Focused on maximising the potential of scientific breakthroughs, Novo Seeds continued to see an increasing number of exciting investment opportunities.
  • Muna Therapeutics, Adcendo and Hemab, three companies that Novo Seeds helped build, each raised significant Series A rounds in excess of US$ 50 million.
  • As a life science investor, Novo Holdings provides seed and venture capital to development-stage companies and takes significant ownership positions in growth and well-established companies.

Novo Seeds Provides Business Update on a Record Year - Building Exceptional Companies for Global Impact

Retrieved on: 
Wednesday, January 12, 2022
Novo Nordisk Foundation, IPO, Growth, NASDAQ, Organon, Novo Nordisk, Industry, Therapy, Seed, Novo Holdings A/S, VCS, Investment, Fine chemical, Financial services, Nordic

Novo Seeds' commitment to early-stage financing and venture creation resulted in an unprecedented amount of capital and interest from fellow VCs across Europe and the US in 2021, with over US$ 550 million raised by Novo Seeds' portfolio companies.

Key Points: 
  • Novo Seeds' commitment to early-stage financing and venture creation resulted in an unprecedented amount of capital and interest from fellow VCs across Europe and the US in 2021, with over US$ 550 million raised by Novo Seeds' portfolio companies.
  • Focused on maximising the potential of scientific breakthroughs, Novo Seeds continued to see an increasing number of exciting investment opportunities.
  • Muna Therapeutics, Adcendo and Hemab, three companies that Novo Seeds helped build, each raised significant Series A rounds in excess of US$ 50 million.
  • As a life science investor, Novo Holdings provides seed and venture capital to development-stage companies and takes significant ownership positions in growth and well-established companies.

2seventy bio Announces Expanded Collaboration Agreement With Novo Nordisk to Continue Development of in vivo Gene Editing Approach

Retrieved on: 
Thursday, January 6, 2022
Science, Cardiology, Biotechnology, Research, Pharmaceutical, Oncology, Health, Genetics, Haemophilia A, Blood, Organic acid, Vaccine, Megat Burhainuddin, Liver, RNA transfection, Vivo, Gene editing, Translation, Haemophilia, Research, Patient, LNP, DNA, Obesity, Goal, HES, Social media, Compte rendu, Bluebird bio, U.S. Securities and Exchange Commission, Twitter, Security (finance), Disease, Diabetes, TAL, NASDAQ, LinkedIn, Conditional sentence, FDA, Partnership, Genome, RNA, Sale, TIME, Multiple myeloma, Novo Nordisk, YouTube, Technology, Risk, CAR, Novo, Lists of diseases, Factor VIII, Pharmaceutical industry, Video game console, Carla Geneve, Facebook

2seventy bio, Inc. (NASDAQ:TSVT) today announced that it has entered into an option and license agreement with Novo Nordisk for joint research and development of an in vivo gene editing treatment for hemophilia A.

Key Points: 
  • 2seventy bio, Inc. (NASDAQ:TSVT) today announced that it has entered into an option and license agreement with Novo Nordisk for joint research and development of an in vivo gene editing treatment for hemophilia A.
  • We are also excited to announce a partnership between 2seventy bio and Genevant Sciences for the use of Genevants lipid nanoparticle (LNP) platform in our collaboration with Novo Nordisk.
  • The collaboration agreement with Novo Nordisk builds upon the original research collaboration signed between bluebird bio and Novo Nordisk in 2019, focused on identifying a development gene therapy candidate for people with hemophilia A.
  • Under the terms of the agreement, Novo Nordisk will obtain the option to exclusively license 2seventy bios in vivo mRNA platform and gene editing technology for use in the treatment of patients with hemophilia A.

Aeterna Zentaris to Present at the H.C. Wainwright BioConnect Conference

Retrieved on: 
Wednesday, January 5, 2022
PD, COVID-19, Severe acute respiratory syndrome coronavirus 2, U.S. FDA, Event, Investor, Company, Amyotrophic lateral sclerosis, Adult, Chlamydia, NMOSD, Neuromyelitis optica spectrum disorder, Conference, TSX, NASDAQ, FDA, Diagnosis, GLOBE, ALS, Hypoparathyroidism, European Commission, Novo Nordisk, Pharmaceutical industry

CHARLESTON, S.C., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (Aeterna or the Company), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today announced that Dr. Klaus Paulini , Chief Executive Officer of Aeterna Zentaris, will present at the virtual H.C. Wainwright Bio C onnect Conference taking place January 10-13, 2022.

Key Points: 
  • CHARLESTON, S.C., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (Aeterna or the Company), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today announced that Dr. Klaus Paulini , Chief Executive Officer of Aeterna Zentaris, will present at the virtual H.C. Wainwright Bio C onnect Conference taking place January 10-13, 2022.
  • The webcast replay will be archived for 90 days following the event.
  • Aeterna Zentaris is a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products focused on areas of significant unmet medical need.
  • Additionally, the Company is developing an oral prophylactic bacterial vaccine against SARS-CoV-2 (COVID-19) and chlamydia.

Hemab Therapeutics Appoints John Maraganore as Chair of Board of Directors and Welcomes New Additions to Board and Leadership Team

Retrieved on: 
Wednesday, January 5, 2022
Linda, Blood, The, Therapy, Development, Program, Doctor of Philosophy, Thrombosis, Research, Patient, Bleeding, Hemostasis, Bluebird bio, All India Mahila Congress, Haemophilia, Fidelity Investments, CEO, Chairperson, AstraZeneca, MBA, Senior, Coagulopathy, Health equity, RNA, Board, Novo Nordisk, RNA interference, Cancer, Novo Holdings A/S, Standard of care, Drug development, CFO, Multimedia, Hematology, Adverum Biotechnologies, Biotechnology, Leadership, HealthCap, Pharmaceutical industry, Management, Genzyme, MD, Genmab, Alnylam Pharmaceuticals

"We are both honored and pleased that John has accepted the role as independent Board Chair, and I personally look forward to working with John to bring Hemab's vision to fruition."

Key Points: 
  • "We are both honored and pleased that John has accepted the role as independent Board Chair, and I personally look forward to working with John to bring Hemab's vision to fruition."
  • "John brings unprecedented experience, passion, and drive to deliver new innovative treatments to patients with underserved bleeding and thrombosis disorders.
  • A veteran of the biotech industry, Dr. Maraganore brings decades of experience in business and scientific thought leadership and strategic product development to the role of Board Chair.
  • "Hemab is in a unique position to deliver truly transformative therapies for patients with rare blood disorders," said Dr. Maraganore.

These are the Top 17 Best Places to Work in Middle East for 2021

Retrieved on: 
Wednesday, December 29, 2021
Novo Nordisk, Organization, AstraZeneca, EAU, Edenred, Program, Management

DUBAI, EAU, Dec. 28, 2021 /PRNewswire/ -- The Best Places to Work organization announced today the top 17 Best Places to Work in Middle East for 2021.

Key Points: 
  • DUBAI, EAU, Dec. 28, 2021 /PRNewswire/ -- The Best Places to Work organization announced today the top 17 Best Places to Work in Middle East for 2021.
  • Topping this year's ranking was Novo Nordisk, the global healthcare company followed by AstraZeneca, the multinational pharmaceutical and biotechnology company.
  • The program recently compiled its annual list of the top 17 Best Places to Work in Middle East ranking based on the assessment of over 250 organizations across the region.
  • The list of the top 17 Best Places to Work in Middle East for 2021:

These are the Top 17 Best Places to Work in Middle East for 2021

Retrieved on: 
Wednesday, December 29, 2021
Novo Nordisk, Organization, AstraZeneca, EAU, Edenred, Program, Management

DUBAI, EAU, Dec. 28, 2021 /PRNewswire/ -- The Best Places to Work organization announced today the top 17 Best Places to Work in Middle East for 2021.

Key Points: 
  • DUBAI, EAU, Dec. 28, 2021 /PRNewswire/ -- The Best Places to Work organization announced today the top 17 Best Places to Work in Middle East for 2021.
  • Topping this year's ranking was Novo Nordisk, the global healthcare company followed by AstraZeneca, the multinational pharmaceutical and biotechnology company.
  • The program recently compiled its annual list of the top 17 Best Places to Work in Middle East ranking based on the assessment of over 250 organizations across the region.
  • The list of the top 17 Best Places to Work in Middle East for 2021: